Overview The research pharmacists are responsible for receipt, storage formulating and dispensing medications for subjects on DF/HCC investigational protocols. DFCI coordinates the DF/HCC efforts to have common systems to manage investigational activities. There are three full-time research pharmacists at DFCI, a pediatric clinical pharmacy specialist and an adult clinical pharmacy specialist that review the treatment protocols. The research pharmacists are responsible for: ? Protocol review and for representing pharmacy at the various committees - CLINPOC, Operations and Audit Subcommittees, including SRC and IRB. ? Creation, approval and activation of on-line standing order templates to facilitate the actual process of ordering medication. ? Obtaining, storing, formulating and dispensing drugs for patients on investigational protocols. ? Maintaining the records in accordance with FDA and NCI guidelines. As part of the DF/HCC, the DFCI research pharmacy also coordinates drug distribution to affiliate institutions and monitors their usage. The coordination of drug distribution includes completion of drug accountability records, generation of site-specific paperwork and receipts, as well as online confirmation that a site is eligible to receive the drug. A new automated Chemo Order Entry (COE) system links specific pharmacy orders for all experimental protocols with protocol templates and with the QACT registration system and thus provides an additional measure in assuring patient safety in our clinical trials. Monthly meetings, standardization of policies and procedures, training of affiliate staff members, quality assurance indicators and coordination of drug inventory for the DF/HCC sites are also coordinated by the DFCI Research Pharmacy. The Research Pharmacists at each site are as follows: ? BIDMC - Keith Belken ? CHB -James Bennett ? DFCI - Caroline Harvey, Mark Sudol, Peter Ng ? MGH - Lalit Joshe ? BWH- Jon Silverman The pharmacy performed 377 full protocol reviews for the SRC and IRB in the calendar year 2003. Our protocol review process requires a detailed pharmacy review of the entire protocol document and supporting literature, with the primary focus on the pharmaceutical information, treatment, adverse events and consent sections. The pharmacist's review ensures that the sections are complete, understandable, accurate and consistent throughout the protocol document. Prior to protocol activation, the Research Pharmacy conducts a final review to assure all concerns have been addressed and the protocol, as written, can be conducted in a safe manner. During 2004 there were approximately 300 protocol order templates online and at least 300 chemotherapy (non-protocol) regimen templates online.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-46
Application #
8038413
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
46
Fiscal Year
2010
Total Cost
$248,733
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917

Showing the most recent 10 out of 411 publications